In a new report, ‘Behind the Price Tag’, the Association of European Cancer Leagues (ECL) has renewed calls for a major overhaul of the EU’s pharmaceutical pricing rules, arguing that the EU’s long-standing Transparency Directive no longer reflects the realities of today’s medicines market.
“The Directive has not evolved with the pharmaceutical market and risks becoming increasingly disconnected from its realities. A comprehensive revision is now essential,” says ECL Executive Director, Wolfgang Fecke.
Adopted in 1989, the Transparency Directive aimed to ensure that national decisions on the pricing and reimbursement of medicines were transparent, predictable, and delivered within set timelines.
More than three decades later, however, the pharmaceutical landscape has changed dramatically. Confidential disc…
